Derived polypeptides formed by modifying structures of frog skin antibacterial peptides AR-23 and application of derived polypeptides

A technology of antimicrobial peptides and polypeptides, which is applied in the fields of application, antibacterial drugs, and medical preparations containing active ingredients, etc., which can solve problems such as side effects, decreased hemolytic activity, and impact on the application prospects of antibacterial drugs

Inactive Publication Date: 2014-10-22
FIELD OPERATION BLOOD TRANSFUSION INST OF PLA SCI ACAD OF MILITARY
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The non-selective cytotoxicity of Melittin can induce serious side effects, which seriously affects its application prospect as an antibacterial drug
Studies have shown that among the 1-20 amino acids of melittin, amino acids such as Leu-6, Lys-7, Val-8, Leu-9, Leu-13, Leu-16, Ile-17, Trp-19 and Ile-20 are antibacterial Hemolytic and hemolytic effects are very important, and deletion of any amino acid will lead to a sharp decline in hemolytic activity and weaken the antibacterial activity (Blondelle SE, Houghten RA. Hemolytic and antimicrobial activities of the twenty-four individual omission analogues of melittin. Biochemistry. 1991May14 ;30(19):4671-8)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Derived polypeptides formed by modifying structures of frog skin antibacterial peptides AR-23 and application of derived polypeptides
  • Derived polypeptides formed by modifying structures of frog skin antibacterial peptides AR-23 and application of derived polypeptides
  • Derived polypeptides formed by modifying structures of frog skin antibacterial peptides AR-23 and application of derived polypeptides

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0071] Embodiment 1, the synthesis of polypeptide A1-A7

[0072] This application reconstructed the sequence of AR-23, and synthesized the modified derivative polypeptides of the frog skin antimicrobial peptide AR-23 named A1-A7, as shown in Table 1, the amino acid sequence of A7 is the SEQ ID No in the sequence table .1. It can be seen from the amino acid sequence that SEQ ID No.2 consists of 23 amino acid residues, and is a derivative polypeptide obtained by mutating Arg at the first and eighth positions of SEQ ID No.1 into Ala respectively. The polypeptide is named A3; SEQ ID No.3 consists of 23 amino acid residues, and is a derivative polypeptide obtained by mutating Arg at position 8 of SEQ ID No.1 to Ala, and the derived polypeptide is named A5; SEQ ID No. .4 consists of 23 amino acid residues, and is a derivative polypeptide obtained by mutating Arg at position 1 of SEQ ID No.1 to Ala, and the derivative polypeptide is named A6; SEQ ID No.5 consists of 23 amino acid re...

Embodiment 2

[0077] Example 2. Identification of Polypeptide A1-A7's Ability to Lyse Erythrocytes

[0078] The experiment was repeated three times, and the experimental method for each repetition was as follows:

[0079] Fresh human erythrocytes were washed three times with PBS buffer, and prepared into 1.25% (v / v) erythrocyte suspension with PBS buffer. Dissolve the polypeptides A7, A1, A2, A3, A4, A5 and A6 obtained in Example 1 with different volumes of PBS buffer solution respectively, and make polypeptide A7 solution, A1 solution, A2 solution, A3 solution, A4 solution, A5 solution and A6 solution. At the same time, AR-23, RV-23 and melittin were used as a comparative experiment, and different concentrations of AR-23 solution, RV-23 solution and melittin solution were prepared. Take 40 μL of different concentrations of polypeptide A7 solution, A1 solution, A2 solution, A3 solution, A4 solution, A5 solution, A6 solution, AR-23 solution, RV-23 solution and melittin solution, and add it...

Embodiment 3

[0085] Embodiment 3, the minimum inhibitory concentration of polypeptide A1-A7 to different bacteria

[0086] The minimum inhibitory concentrations of polypeptides A1-A7 to different bacteria were identified by the micro-dilution method using a 96-well plate. The experiment was repeated three times, and the method of repeating the experiment each time was as follows:

[0087] Escherichia coli (China General Microbiology Collection Center, number: 1.3373), Pseudomonas aeruginosa (China General Microbiology Collection Center, number: 1.2620), Staphylococcus aureus (China General Microbiology Collection Center, number: 1.2910) and Staphylococcus epidermidis (China Center for Common Microorganisms Collection, No. 1.4260) were streaked and inoculated onto LB plates respectively, and spent overnight at 37. Pick single colonies of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus and Staphylococcus epidermidis respectively in ordinary LB medium, culture at 37 degrees a...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a group of derived polypeptides formed by modifying the structures of frog skin antibacterial peptides AR-23 and an application of the derived polypeptides. The group of derived polypeptides are named as A1-A7, and have amino acid sequences, i.e., respectively SEQ ID No.1, SEQ ID No.2, SEQ ID No.3, SEQ ID No.4, SEQ ID No.5, SEQ ID No.6 and SEQ ID No.7. The experiment proves that compared with natural antibacterial peptides, according to the derived polypeptides formed by modifying the structures of frog skin antibacterial peptides AR-23, the selective toxicity of the derived polypeptides to bacteria is high while the toxicity of the derived polypeptides to human cells is obviously decreased, so that the influences of the derived polypeptides to somatic cells, red blood cells and the like are very low. The polypeptides A1-A7 have broad-spectrum killing effects on gram-positive bacteria or gram-negative bacteria, so that the polypeptides A1-A7 can be used for treating diseases caused by the infections of the gram-positive bacteria or the gram-negative bacteria resistant to antibiotics.

Description

technical field [0001] The invention relates to a modified derivative polypeptide of the frog skin antibacterial peptide AR-23 and its application in the field of biotechnology. Background technique [0002] Bacterial resistance to antibiotics has become a major problem threatening human health. Antibacterial peptide (Antibacterial Peptide) is a defensive peptide active substance produced by organisms against the invasion and pathogenicity of exogenous pathogens. It is an important part of the body's immune defense system. Antimicrobial peptides: an overview of a promising class of therapeutics. Central European Journal of Biology, 2007, 2(1): 1-33). [0003] Natural antimicrobial peptides are generally composed of 10-50 amino acids. The C-terminal is rich in hydrophilic amino acids, while the N-terminal contains more hydrophobic residues and has an amphipathic structure. Studies have shown that antimicrobial peptides can form holes on the surface of bacteria through modes...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07K14/46C12N15/12A61K38/17A61P31/04
CPCA61K38/00C07K14/463
Inventor 季守平张士坤檀英霞宫锋李素波高红伟冷泠
Owner FIELD OPERATION BLOOD TRANSFUSION INST OF PLA SCI ACAD OF MILITARY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products